Platelet-Derived Transforming Growth Factor-β Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity
Open Access
- 1 October 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (19), 7775-7783
- https://doi.org/10.1158/0008-5472.can-09-2123
Abstract
Natural killer (NK) cells play an important role in cancer immunosurveillance and may prevent tumor progression and metastasis due to their ability to mediate direct cellular cytotoxicity and by releasing immunoregulatory cytokines, which shape adaptive immune responses. Their reactivity is governed by various activating and inhibitory molecules expressed on target cells and reciprocal interactions with other hematopoietic cells such as dendritic cells. In mice, thrombocytopenia inhibits metastasis, and this is reversed by NK cell depletion, suggesting that platelets are an important additional player in NK cell-tumor interaction. Moreover, it has been shown that metastasizing tumor cells do not travel through the blood alone but are rapidly coated by platelets. However, the knowledge about the molecular mechanisms by which platelets influence NK cells is fragmentary at best. Here we show that platelet-derived soluble factors, secreted on coating of tumor cells or after stimulation with classic platelet agonists, impair NK cell antitumor reactivity resulting in diminished granule mobilization, cytotoxicity, and IFN-γ production. The impaired NK cell reactivity was not due to induction of apoptosis but mediated by down-regulation of the activating immunoreceptor natural killer group 2, member D (NKG2D) on NK cells by platelet-derived transforming growth factor β (TGF-β). Neutralization of TGF-β in platelet releasate not only prevented NKG2D down-regulation but also restored NK cell antitumor reactivity. Thus, our data elucidate the molecular basis of the previously described influence of platelets on NK cell antitumor reactivity and suggest that therapeutic intervention in tumor cell-platelet interaction and the resulting TGF-β release by platelets may serve to enhance antitumor immunity. [Cancer Res 2009;69(19):7775–83]Keywords
This publication has 39 references indexed in Scilit:
- Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor β SignalingJNCI Journal of the National Cancer Institute, 2009
- In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-β1Blood, 2008
- Up on the tightrope: natural killer cell activation and inhibitionNature Immunology, 2008
- Natural killer cell–directed therapies: moving from unexpected results to successful strategiesNature Immunology, 2008
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous MalignancyImmunity, 2008
- Promiscuity and the single receptor: NKG2DNature Reviews Immunology, 2007
- Tumor cell–associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell–dependent and–independent mechanismsBlood, 2007
- Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytesNature Medicine, 2006
- NK CELL RECOGNITIONAnnual Review of Immunology, 2005
- Antimetastatic effects associated with platelet reduction.Proceedings of the National Academy of Sciences of the United States of America, 1968